INTRODUCTION
============

Parvovirus B19 (B19) is commonly known as a causative pathogen of erythema infectiosum in children. The virus also provokes various severe diseases, such as hematological disorders, hepatitis and encephalitis.^[@ref1]-[@ref3])^ Acute B19 infection is often accompanied by autoantibody formation, including antinuclear antibodies (ANA) and rheumatoid factor (RF), and the symptoms of the infection are similar to those of several autoimmune diseases.^[@ref4])^ Uveitis is a representative manifestation of autoimmune diseases and is sometimes caused by various pathogens. Three cases with B19-associated uveitis were previously reported,^[@ref5]-[@ref7])^ but the pathophysiology was unknown. We herein report the first pediatric case of B19-associated uveitis without autoantibody formation during the acute phase of primary infection of B19.

CASE REPORT
===========

A previously healthy 9-year-old boy visited our hospital for the evaluation and treatment of uveitis. Seven days before the initial visit, bilateral redness of the bulbar conjunctiva was noted, and the patients developed a fever and ophthalmalgia 5 days before the initial visit. An ophthalmic medical practitioner diagnosed him with iritis. He was referred to us for further management. He was already afebrile at the initial visit to our hospital. No abnormal physical findings were revealed, except for redness of the conjunctiva. The presence of a large amount of cells in the anterior chamber (3+) and bilateral papilledema on direct ophthalmoscopy and dye leakage from retinal vessels in fluorescein fundus angiography led to the diagnosis of panuveitis ([Fig. 1](#fig1){ref-type="fig"}).

![Funduscopic findings at the initial visit to our hospital. Papilledema (black arrow) was found on direct ophthalmoscopy (A) and fluorescein fundus angiography showed dye leakage (black arrow) from retinal vessels (B).](2186-3326-80-0611-g001){#fig1}

Complete blood counts showed a leukocyte count of 8.9×10^9^ /L with 82% neutrophils, a hemoglobin concentration of 13.6 g/dL and a platelet count of 299×10^9^ /L. Blood chemistry analyses showed an aspartate aminotransferase level of 91 IU/L, an alanine aminotransferase level of 155 IU/L and a lactate dehydrogenase level of 279 IU/L. The C-reactive protein concentration was 2.27 mg/dL, and the erythrocyte sedimentation rate was 59 mm/h. Neither hypocomplementemia nor hypergammaglobulinemia was shown. ANA, anti-double stranded DNA antibodies and anti-SSA and anti-SSB antibodies were undetectable, and RF (4.3 U/mL, reference range \< 15) and angiotensin-converting enzyme (6.8 IU/L, reference range 8.3--21.4) were not elevated. Serologic tests for *Toxoplasma gondii*, *Bartonella henselae* and human T-cell leukemia virus type 1 indicated no previous infection, and that for cytomegalovirus showed a past or current inactive infection. The ophthalmalgia and redness of the conjunctiva were ameliorated after starting topical steroid therapy, whereas mild papilledema persisted. Three weeks after the onset of symptoms, erythema of the bilateral cheeks and upper arms appeared. Serum anti-B19 IgM antibody was positive. Neither ANA nor RF was elevated. B19-DNA was detected from the serum sample obtained at the initial visit to our hospital (1×10^7^ copies/mL), whereas anti-B19 IgG and IgM antibodies were undetectable. Based on these results, we diagnosed him with B19-associated uveitis. The abnormal funduscopic findings disappeared at the 5th month of illness with continuous topical steroid therapy alone.

DISCUSSION
==========

Only 1 of the 3 previously reported cases developed B19-associated uveitis before the appearance of erythema ([Table 1](#table1){ref-type="table"}),^[@ref5]-[@ref7])^ indicating that the present case was the second reported case with the disease during the acute phase of B19 infection. Whether B19-associated uveitis is caused by the direct invasion of the virus or the induction of autoimmunity remains unclear. Autoantibodies, which are believed to play a central role in the development of autoimmune disorder-related uveitis,^[@ref8])^ are often detected during B19 infection. In a previous study, ANAs were detected in 65% of patients with B19 infection.^[@ref9])^ Two reported cases of B19-associated uveitis showed elevated levels of autoantibodies and positive results ([Table 1](#table1){ref-type="table"}), thus indicating that autoantibodies appear to play some role in the immunological process.^[@ref6]-[@ref7])^ However, the prevalence of antibodies against non-structural protein NS-1 of B19 and the detection rate of viral DNA in the serum were higher in the patients with uveitis than in healthy individuals.^[@ref10])^ Serum anti-B19-specific antibodies in the present case were undetectable at the onset of uveitis, and no autoantibody formation occurred over the course of the disease, suggesting that B19 might directly invade the eye.

###### 

Reported patients with parvovirus B19-associated uveitis

  Pt.   Age   Sex   Appearance of erythema   Timing of the onset of uveitis                    Autoantibody detected from sera   Treatment         Outcome    Complication    Ref.
  ----- ----- ----- ------------------------ ------------------------------------------------- --------------------------------- ----------------- ---------- --------------- ------
  1     18    F     Yes                      After a few weeks of the appearance of erythema   Unknown                           Topical steroid   Improved   Adie's pupils   5
  2     6     F     No                       Development of only uveitis                       RF                                Topical steroid   Improved                   6
  3     5     F     Yes                      Before 2 weeks of the appearance of erythema      ANA                               Topical steroid   Improved   Epilepsy        7
  4     9     M     Yes                      Before 3 weeks of the appearance of erythema      None                              Topical steroid   Improved                   Ours

There is no specific treatment for the elimination of B19. Intravenous immunoglobulin (IVIG) therapy is performed for immunocompromised patients with chronic B19 infection, patients with chronic hemolytic disorders or patients with severe B19 infection, including encephalitis and myocarditis,^[@ref11]-[@ref14])^ whereas B19 infection spontaneously improves in immunocompetent patients. In the present case, uveitis was not worsened at the diagnosis of erythema infectiosum. As erythema usually appears after the viremia has cleared, IVIG therapy was not needed for the present patient. However, topical steroid therapy seemed to be necessary in the present case because of the limited therapeutic options available for childhood uveitis of unknown etiology.^[@ref15])^

B19 is preferentially replicated in erythroid progenitor cells but has also been found to persist in many other non-erythroid tissues.^[@ref16])^ B19 capsid RNA or proteins have been detected in tissues from the colon, heart, liver and lymphoid, synovial, testicular and thyroid and have been associated with increased inflammatory-related gene expression.^[@ref16],[@ref17])^ However, the mechanism underlying the invasion to these tissues is unknown. The present case suggests that B19 may also have a high affinity for tissue in the eye. The accumulation of more patients with B19-associated uveitis is needed to determine the pathophysiology of the development of the disease.
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